<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How did ESPR's Q1 2024 EPS outperform forecasts?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        4/10/2025 06:17pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Esperion Therapeutics, Inc. (ESPR) reported an EPS of -$0.11 for Q1 2024, which is less than the EPS of $0.08 that was forecasted by Zacks Research for Q2 2024. This indicates that ESPR's Q1 2024 EPS did not outperform forecasts. In fact, it missed the forecast by a significant margin, suggesting that the company's performance for this quarter was below expectations.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am){return {layout:"default",data:[{noData:c,currentQuestion:d,textDescription:E,comeFrom:"AInvestShareLink",events:[],answerSource:l}],fetch:{},error:m,state:{sharePreviewModule:{loadJgySuccess:f,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:1,agent_id:a,output_media_info:[],task_id:a,language:a,source:l,cache_builder:a,reply_action:"Answer",execute_mode:u,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did ESPR's Q1 2024 EPS outperform forecasts?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did ESPR's Q1 2024 EPS outperform forecasts?\",\"user_id\":\"dp75273337\",\"user_name\":\"\",\"trace_id\":\"9fd7a19f-f6c3-4bc7-a709-1516ee493fc7\",\"session_id\":\"9fd7a19f-f6c3-4bc7-a709-1516ee493fc7\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"search",raw_data:{number:r,title:F,summary:G,full_summary:"Get Esperion Therapeutics alerts: Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Analysts at Zacks Research dropped their Q4 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued to investors on Tuesday, May 21st. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings per share of $0.08 for the quarter, down from their prior forecast of $0.14. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.17) per share. Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03. The business had revenue of $32.25 million for the quarter, compared to analyst estimates of $26.84 million. During the same quarter last year, the company earned ($0.76) earnings per share. A number of other equities analysts also recently commented on ESPR. Needham & Company LLC reissued a “buy” rating and set a $8.00 price objective on shares of Esperion Therapeutics in a research report on Tuesday, May 7th. StockNews.com cut shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, May 17th. Finally, HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a report on Tuesday. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Esperion Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.33. View Our Latest Stock Report on Esperion Therapeutics Esperion Therapeutics Price Performance ESPR opened at $2.38 on Wednesday. The business has a fifty day moving average price of $2.31 and a 200 day moving average price of $2.17. Esperion ",url:H,image_url:a,video_url:a,publish_time:I,search_extra_info:{search_burial_info:{id:J,uid:v,ab:{scene_id:K,layer_exp:[{layer_id:L,exp_id:M}]}}},simhash:"6bd91e6972c113aa",msg_id:v}}],answer_chain_name:N,agent_mode:O,native_answer:a,come_from:a,text_answer:E,trace_id:e,cost:14362,event_names:a,question:d,fallback_type:P,input_type:Q,fall_back_reason:{fall_back_type:P,risk_detail:{matched_words:[]}},session_id:e,first_return_cost:3427,cache_type:a,question_id:e,transfer_question:d,signal_type:"ON_COMPLETE",start_time:R,remote_svc:l,slots:[],answer_type:u,user_id:s,skill_name:w},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:e,session_id:e,user_id:s,question:d,source:l,raw_question:d,version:"3.4.1",action_name:w,nlu:{entity:[{type:S,value:"ESPR.O",market:T}]},deep_research:c,deep_thinking:c,agent_mode:O},extra:{}},{answer_path:g,section:{id:h,info_texts:["Thinking"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:g,section:{id:h,info_texts:["Querying Stock: ESPR EPS Surprise, EPS, Revenue, Net Income in Fiscal Q1 2024"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:x},logs:[],extra:{action:U,action_input:"ESPR EPS Surprise, EPS, Revenue, Net Income in Fiscal Q1 2024",thought:y}},{answer_path:g,section:{id:h,info_texts:["Querying Stock: ESPR Average Analyst Price Target, Consensus Rating"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:x},logs:[],extra:{action:U,action_input:"ESPR Average Analyst Price Target, Consensus Rating",thought:y}},{answer_path:g,section:{id:h,info_texts:["Searching Web: Esperion Therapeutics analyst opinions"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:x},logs:[],extra:{action:"Searching Web",action_input:"Esperion Therapeutics analyst opinions",thought:y}},{answer_path:j,section:{id:V,info_texts:[],show_type:z,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:V,info_texts:[],show_type:z,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:g,section:{id:h,info_texts:["Generating Answer"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:j,section:{id:A,info_texts:[],show_type:B,voice_txt:"Es",text_answer:W,rich_text:W,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:2000,info_texts:[],show_type:B,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:H,image_url:a,video_url:a,title:F,summary:G,index:r,publish_time:I,search_id:J,search_uid:v,search_ab:{scene_id:K,layer_exp:[{layer_id:L,exp_id:M}]},jump_type:"normal"}],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:A,info_texts:[],show_type:B,voice_txt:". This",text_answer:X,rich_text:X,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:j,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"ESPR",market_id:T,name:Y,domain:S},pos:f,section_id:A,txt:Y,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:g,section:{id:h,info_texts:["Completed"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:n,query_text:n,trace_info:{item_id:"0f44939e84d52ea045a501aeaef52e93",item_type:k,item_name:n,rec_info:Z}},{display_text:o,query_text:o,trace_info:{item_id:"c7f266803b07e9f05a162baed2eeb16c",item_type:k,item_name:o,rec_info:_}},{display_text:p,query_text:p,trace_info:{item_id:"d01fa793b538384571e1b01cf0442e5b",item_type:k,item_name:p,rec_info:$}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:f,type:"1",display2:c,url:a}},request_config:[{source_type:r,related_name:aa}],puuid:C,tag:a,category:"custom",uuid:ab}],global:{urp_static_data:[{name:aa,value:{status_code:f,columns:[{type:q,index_name:ac,key:ac},{type:q,index_name:ad,key:ad},{type:q,index_name:ae,key:ae},{type:q,index_name:af,key:af},{type:q,index_name:ag,key:ag}],datas:[{send_text:n,item_type:k,rec_info:Z,display_text:n,rec_reason:a},{send_text:o,item_type:k,rec_info:_,display_text:o,rec_reason:a},{send_text:p,item_type:k,rec_info:$,display_text:p,rec_reason:a}],dataSize:r,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ah,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:t,"min-height":"100%",position:ai,height:t},isMaterial:c,id:ah,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:f,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:D,componentUuid:ab,script:[{name:aj,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:D,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:D},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:t,position:ai,height:t},isMaterial:b,_id:19,id:aj,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:ak,voice_txt:a,tracking_info:{},uuid:C},order:{is_auto:c,render_for:ak,chart_type:"command",puuid:C}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1005,info_texts:[],show_type:z,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:w,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:u,answer_chain_name:N},is_deep_research:c,deep_thinking:c,create_time:1744280288906},is_last:b}],questionItem:{data:{qStr:d,encodeFlag:c,imageData:m,docsData:[],quoteData:m},tplType:"question"},events:al,agentId:a,param:{entity_info:{},add_info:{ori_question:d},event_list:al,client_ip:a,question:d,user_id:s,user_name:a,trace_id:e,session_id:e,source:l,input_type:Q}}],userId:s,userName:a,startTime:R,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:m,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:f,traceTableData:m,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-esprs-q1-2024-eps-outperform-forecasts-2a3d03\u002F",config:{_app:{basePath:am,assetsPath:am,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"How did ESPR's Q1 2024 EPS outperform forecasts?","9fd7a19f-f6c3-4bc7-a709-1516ee493fc7",0,"progress\u002Fsearching_for",1000,"searching_for","other\u002FopenAnswer","llm_generated","ths_ainvest_lite_web",null,"What is the current analyst consensus for ESPR's future EPS growth?","Were there any one-time items or adjustments that affected ESPR's Q1 2024 EPS?","What were the key factors behind ESPR's Q1 2024 EPS beat?","STR",3,"dp75273337","auto","agent","e4ef51846590734e","explain news events","thinking","The user wants to analyze why ESPR's Q1 2024 EPS exceeded forecasts. I should focus on actual EPS, forecast EPS, revenue, net income, and analyst opinions. I will use FinQuery for the data mentioned above; use Search for analyst opinions.","signal",2001,"rich_text","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Esperion Therapeutics, Inc. (ESPR) reported an EPS of -$0.11 for Q1 2024, which is less than the EPS of $0.08 that was forecasted by Zacks Research for Q2 2024. This indicates that ESPR's Q1 2024 EPS did not outperform forecasts. In fact, it missed the forecast by a significant margin, suggesting that the company's performance for this quarter was below expectations.","Q4 2025 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Reduced by Analyst","Get Esperion Therapeutics alerts: Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Analysts at Zacks Research dropped their Q4 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued to investors on Tuesday, May 21st. Zacks Research analyst K. D...","https:\u002F\u002Fwww.americanbankingnews.com\u002F2024\u002F05\u002F23\u002Fq4-2025-eps-estimates-for-esperion-therapeutics-inc-nasdaqespr-reduced-by-analyst.html","2024-05-22","e4ef51846590734e_0","oeqxkhszf","oeqxkhszf_layer","base","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite",1744280274545,"stock","185","Querying Stock",999,"Esperion Therapeutics, Inc. (ESPR) reported an EPS of -$0.11 for Q1 2024, which is less than the EPS of $0.08 that was forecasted by Zacks Research for Q2 2024[^3]",". This indicates that ESPR's Q1 2024 EPS did not outperform forecasts. In fact, it missed the forecast by a significant margin, suggesting that the company's performance for this quarter was below expectations.","Esperion","2+679_496_21_554+0+0+9fd7a19f-f6c3-4bc7-a709-1516ee493fc7+0f44939e84d52ea045a501aeaef52e93+llm_generated+aimeTagAnalysis+0+0.0901469737291336+1","2+679_496_21_554+0+0+9fd7a19f-f6c3-4bc7-a709-1516ee493fc7+c7f266803b07e9f05a162baed2eeb16c+llm_generated+aimeTagAnalysis+0+0.07976552844047546+2","2+679_496_21_554+0+0+9fd7a19f-f6c3-4bc7-a709-1516ee493fc7+d01fa793b538384571e1b01cf0442e5b+llm_generated+aimeTagAnalysis+0+0.06750743091106415+3","recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>